CD8 T cell defect of TNF-α and IL-2 in DNAM-1 deficient mice delays clearance in vivo of a persistent virus infection  by Welch, Megan J. et al.
Virology 429 (2012) 163–170Contents lists available at SciVerse ScienceDirectVirology0042-68
http://d
n Corr
E-mjournal homepage: www.elsevier.com/locate/yviroCD8 T cell defect of TNF-a and IL-2 in DNAM-1 deﬁcient mice delays
clearance in vivo of a persistent virus infectionMegan J. Welch a, John R. Teijaro a, Hanna A. Lewicki a, Marco Colonna b, Michael B.A. Oldstone a,n
a Department of Immunology and Microbial Science, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
b Department of Pathology and Immunology, Washington University School of Medicine, 660S Euclid Avenue, St. Louis, MO 63110, USAa r t i c l e i n f o
Article history:
Received 22 December 2011
Returned to author for revisions
3 February 2012
Accepted 13 April 2012
Available online 12 May 2012
Keywords:
DNAM-1 deﬁciency
Acute LCMV infection
Persistent LCMV infection
T cell defects22/$ - see front matter & 2012 Elsevier Inc. A
x.doi.org/10.1016/j.virol.2012.04.006
esponding author. Fax: þ1 858 784 9981
ail address: mbaobo@scripps.edu (M.B.A. Olda b s t r a c t
DNAM-1 gene-deﬁcient (/) mice take signiﬁcantly longer to clear an acute and persistent LCMV
infection in vivo than DNAM-1 þ/þ mice. During acute LCMV priming, at the single cell level, DNAM-1
/ mice made signiﬁcantly less cytoplasmic CD8 TNF-a and IL-2 but not IFN-g than their DNAM-1
þ/þ counterparts. Restimulated immune memory CD8 T cells from DNAM-1 / and DNAM-1 þ/þ
mice were equivalent in cytolytic activity against LCMV-infected target cells but DNAM-1 / CD8
T cells had signiﬁcant reductions in TNF-a and IL-2 that were associated on adoptive transfer with the
inability to terminate the persistent viral infection.
& 2012 Elsevier Inc. All rights reserved.Introduction
DNAM-1 (also called DNAX activating molecule 1, CD226) is
associated with the activation of cytotoxic lymphocytes by non-
professional antigen-presenting cells and tumors (Gilﬁllan et al.,
2008). DNAM-1 is an adhesion molecule on CD8 T cells and NK
cells and may play a role in the recognition of and response to
viruses and tumor cells (Linn et al., 2009; Magri et al., 2011;
Nabekura et al., 2010; Pende et al., 2006; Pende et al., 2005;
Shibuya et al., 1996; Shibuya et al., 1999).
Utilizing DNAM-1 gene disrupted (/) mice, Gilﬁllan and
colleagues (Gilﬁllan et al., 2008) showed that CD8 T cells required
DNAM-1 for co-stimulation when recognizing antigen presented
by non-professional antigen-presenting cells but not for dendritic
cells (DC). Moreover, NK cells require DNAM-1 for elimination of
NK-cell resistant tumors. Recently, Cella et al. (2010) when
evaluating CD8 T cells in chronic HIV infection noted that both
progressive CD8 T cell exhaustion and higher viral loads accom-
panied a decrease of DNAM-1 expression combined with an
increase in PD-1 expression (PD-1high, DNAM-1low) on such CD8
T cells. Their observations suggested that DNAM-1 down-regula-
tion on CD8 T cells was one important factor in the impairment of
efﬁcient and effective CD8 CTL antiviral function. They extended
their observation of HIV infection to a persistent infection of mice
with lymphocytic choriomeningitis virus (LCMV) (Cella et al.,ll rights reserved.
stone).2010). There, DNAM-1 expression was also lost on PD-1high CD8
T cells during persistent LCMV infection. A signiﬁcant proportion
of CD8 T cells losing DNAM-1 expression were speciﬁc for the
LCMV H-Db-restricted GP 33–41 immunodominant viral CTL
epitope. However, neither study included the biologic relevance
of these observations nor assessment of virus-speciﬁc CD4 T cells.
LCMV, in its natural murine host, has proven to be a superb
experimental model for dissecting the immune response to acute
as well as persistent infection reviewed (Oldstone, 2002; Oldstone
and Campbell, 2011; Zinkernagel, 2002).
In this report we utilize the LCMV ARM model of acute LCMV
infection and the LCMV Cl 13 model of persistent infection
(Ahmed and Oldstone, 1988; Oldstone and Campbell, 2011) to
dissect in vivo the functional role of DNAM-1 in acute and
persistent infection using DNAM-1 / and DNAM-1 þ/þ hosts.
Our results indicate that following an acute LCMV infection
DNAM-1 / and DNAM-1 þ/þ mice generated antiviral CD8
T cells that efﬁciently purge virus and terminated the infection.
However, on the basis of single cell analysis of the immunodo-
minant H-2b-restricted antiviral CD8 CTL (GP 33–41) or CD4 T cell
(GP 67–77) response using tetramers and peptide stimulation,
DNAM-1 / mice had a signiﬁcant decrease in expression of
TNF-a and IL-2 molecules in their antiviral CD8 T cells when
compared to antiviral CD8 T cells DNAM-1 þ/þ mice. Unexpect-
edly, the virus-speciﬁc CD4 T cells from DNAM-1 / mice
displayed signiﬁcant elevations in expression of TNF-a and IL-2.
However, by deletion studies, CD4 T cells had a negligible effect
on the generation and action of cytolytic CD8 T cells indicating
that the DNAM-1 gene enhanced expression of TNF-a and IL-2 in
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in LCMV infection. When undergoing a persistent Cl 13 infection,
DNAM-1 þ/þ mice spontaneously cleared virus signiﬁcantly
faster than DNAM-1 / mice revealing that the DNAM-1 gene
product plays a signiﬁcant biologic role in the efﬁciency and
effectiveness of antiviral CD8 T cell function in vivo. While the
spontaneous clearance of persistent LCMV infection in DNAM-1
/ mice was signiﬁcantly slower than spontaneous clearance in
DNAM-1 þ/þ mice, virus was ultimately cleared. Further, adop-
tive transfer of immune memory cells from DNAM-1 / mice
were derelict in purging LCMV from persistently infected DNAM-
1 þ/þ mice, while immune memory cells from DNAM-1 þ/þ
mice were efﬁcient and effective. The defect in viral clearance by
immune memory cells from DNAM-1 / mice was not attrib-
uted to the lytic ability of CD8 T cells, generation of CD8 or CD4 T
cell memory cells or manufacture of antiviral antibodies but was
associated with a decrease in TNF-a and IL-2 expression in virus-
speciﬁc CD8 T cells.Results
DNAM-1  / mice generate an antiviral-speciﬁc CD8 cytotoxic T
cell response that efﬁciently clears an acute infection with LCMV
Armstrong 53b (ARM)
Both LCMV-speciﬁc CD8 and CD4 T cell responses are generated
after a primary LCMV infection although the CD8 CTL response
alone, without assistance from CD4 T cells, is necessary and
sufﬁcient to clear an acute LCMV infection according to deletion
and reconstitution experiments (Matloubian et al., 1994; Tishon
et al., 1995). To assess the importance of DNAM-1 in vivo we tracked
the generation and function of anti-LCMV speciﬁc anti-CD8 cyto-
toxic T cells in DNAM-1 / and þ/þ (H-2b) mice. Both groups of
ﬁve to six sex-matched 8-week-old mice were challenged i.p. with
either a low dose (1103 PFU) or a high dose (1105 PFU) of LCMV
ARM 53b. As shown in Table 1, both doses of virus elicited an anti-
LCMV-speciﬁc H-2b MHC-restricted CTL response. Further, that
primary immune response was sufﬁcient to clear the acute virus
infection from DNAM-1 / as well as DNAM-1 þ/þ mice.Table 1
Generation of LCMV-speciﬁc CTL response (day 7P1).
Virus inoculation E:T ratio 51Cr released from LCMV
inf targets
Mice tg H-2b H-2d
1105 PFU ip
H-2b DNAM / 50:1 3878 o1
H-2b DNAM þ/þ 50:1 4573 o1
H-2d DNAM þ/þ 50:1 3 48
1103 PFU ip
H-2b DNAM / 50:1 3672 o1
H-2b DNAM / 25:1 2472 0
H-2b DNAM þ/þ 50:1 2176 0
H-2b DNAM þ/þ 25:1 1373 0
DNAM-1 / and DNAM-1 þ/þ mice generate an effective and efﬁcient CD8
cytotoxic T cell response 7 days following primary challenge with 1105 PFU of
LCMV ARM i.p. Table 1 shows generation of H-2b (Db)-restricted CTL in a
51Chromium (Cr) release assay at different effector (E, lymphocyte) to target
(T, LCMV infected ﬁbroblast targets) ratios. Each sample run in triplicate. Target
cells were MC-57 for H-2b and Balb/Cl 7 for H-2d targets. See Materials and
Methods and (Ahmed and Oldstone, 1988) for details. Data were similar in two
representative assays. 51Cr release numbers represent mean percent of speciﬁc
51Cr releaseþ1 SE.However, in repeated experiments DNAM-1 / mice took longer
(9.471.5 days) than DNAM-1 þ/þ mice (7.270.2 days) to
terminate the acute LCMV infection.
CD8 T Cells from DNAM-1  / mice make signiﬁcantly less TNF-a
and IL-2 than CD8 T Cells from DNAM-1 þ /þ mice at 7, 14, and 30
days following a primary LCMV ARM challenge
To analyze the kinetics of the virus-speciﬁc CD8 and CD4 T cell
response generated at the single-cell level during an acute LCMV
ARM infection, we used GP 33–41 and GP 67–77 tetramers as well
as GP 33–41 and GP 61–80 peptides to identify anti-LCMV-
speciﬁc CD8 and CD4 T cells and determine the ability of such
T cells to make IFN-g, IL-2, and TNF-a (Figs. 1, 2). GP 33 is an
immunodominant H-2Db-restricted CD8þ CTL and recognizes the
GP aa 33–41 LCMV epitope (Klavinskis et al., 1990); GP 61–80 was
ﬁrst described as the immunodominant H-2 IAb-restricted CD4
helper T cell epitope (Varga and Welsh, 1998) and subsequently
ﬁne mapped to GP 67–77 epitope (Homann et al., 2007). For these
experiments four- to six-sex-matched 8-week-old DNAM-1 /
and DNAM-1 þ/þ mice were inoculated with 1105 PFU of
LCMV ARM 53b and their spleens were harvested at 7, 14, and 30
days post-infection. To obtain LCMV-speciﬁc CD8 and CD4 T cell
immune memory responders, 42 days following the primary (P1)
virus inoculation a secondary (S1) challenge was given. At all
times for primary or secondary immune responses the total
number of splenic CD8 and CD4 T cells were equivalent between
DNAM-1 / and DNAM-1 þ/þ mice.
The cytoplasmic expression of IFN-g was then analyzed in GP
33 CD8 and GP 67 CD4 T cells (Fig. 1), and for TNF-a and IL-2,
respectively (Fig. 3). Signiﬁcantly less TNF-a and IL-2 was present
in GP 33 CD8 T cells of DNAM-1 / mice at day 7 (DNAM-1
/ TNF-a/IL-2: 7.8þ0.5 compared to DNAM-1 þ/þ: 12.3þ1.3,
po0.005), at day 14 (DNAM-1 / TNF-a/IL-2: 11.7þ0.5 com-
pared to DNAM-1 þ/þ: 16.2þ1.0, po0.005) post-infection and
at day 30 (DNAM-1 / TNF-a/IL-2: 14.2þ2.0 compared to
DNAM-1 þ/þ TNF-a/IL-2: 23.9þ1.4, po0.005) (Fig. 2). In con-
trast, cytoplasmic expression of the effector molecule IFN-g was
not signiﬁcantly different between groups at day 7, 14, or 30 post-
LCMV challenge (day 7 DNAM-1 / 8.5þ1.9 vs. DNAM-1 þ/þ
9.0þ0.5; day s14 DNAM-1 / 11.1þ0.4 vs. DNAM-1 þ/þ
10.3þ1.0; days 30 DNAM-1 / 9.1 þ0.4 vs. DNAM-1 þ/þ
9.2þ0.3) (Fig. 1). These data represented meansþ1 SD after
subtraction of the negative control for four to six mice per group.
Fig. 1 (left panels) shows the functional analysis for GP 33-speciﬁc
CD8 T cells and GP 61–80-speciﬁc CD4 T cells over the 30 days
observation period for a representative mouse, while the right
panel of Fig. 1 reﬂects the meanþSD of ﬁve mice per group
for each time point. Fig. 2 (upper panel, left) depicts raw data
from one representative DNAM-1 / and DNAM-1 þ/þ mouse
response at day 14 when the TNF-a and IL-2 content was
decreased in GP 33 CD8 T cells from DNAM-1 / mice
compared to DNAM-1 þ/þ mice. Fig. 2 (lower panel, left) shows
at all three assayed times signiﬁcant differences in GP 33 CD8 T
cells where groups of ﬁve DNAM-1 / mice made less TNF-a
and IL-2 than GP 33 CD8 T cells from DNAM-1 þ/þ mice.
Interestingly, when the effector LCMV-speciﬁc GP 67 CD4 T
cells were measured for TNF-a, IL-2, and IFN-g expression,
DNAM-1 / mice had a slight but signiﬁcant up-regulation of
these molecules over DNAM-1 þ/þ mice at day 14 but not at day
7 or 30 post-infection (Fig. 2, right lower panel). While there was
no difference between GP 33 CD8 T cells in expression of IFN-g
at days 7, 14, or 30 between DNAM-1 / and DNAM-1 þ/þ
mice following a primary LCMV ARM challenge, in contrast, in
GP 61–80 immunodominant CD4 T cells, IFN-g was signiﬁcantly
enhanced at days 14 and 30 in DNAM-1 þ/þ mice when
Fig. 1. LCMV-speciﬁc GP 33 CD8 T cells from DNAM-1 / and DNAM-1 þ/þ mice show equivalent expression of interferon-g 7, 15, and 30 days following a primary
challenge with LCMV ARM 1105 i.p. Panels: Left upper: shows representative FACS data from one of ﬁve DNAM-1 / or DNAM-1 þ/þ mice for generation of
interferon-g for GP 33-speciﬁc CD8 T cells harvested from the spleen. The right upper panel shows the meanþ1 SD for the group of ﬁve to six mice each. No signiﬁcant
difference between DNAM-1 / and DNAM-1 þ/þ mice occurred. The bottom panel on the left shows representative FACS data for one of ﬁve mice for expression of
interferon-g in LCMV-speciﬁc GP 61 CD4 T cells at 7, 14, or 30 days following primary LCMV ARM challenge while the lower right panel shows the mean71 SD for the
DNAM-1 / and DNAM-1 þ/þ group. DNAM-1 / mice expressed signiﬁcantly more interferon-g in primed LCMV-speciﬁc GP 61 CD4 T cells at 14 and 30 days when
compared to DNAM-1 þ/þ mice. At day 7 post-inoculation GP 61 CD4 T cells from DNAM-1 / mice expressed more interferon-g than GP 61 CD4 T cells from DNAM-1
þ/þ mice but the difference was not signiﬁcant (P¼0.1). Experiment assaying for interferon-g in GP 33 CD8 and GP 61 CD4 T cells were repeated twice with similar
results. For technical details see (Brooks et al., 2006; Homann et al., 2001; Sullivan et al., 2011).
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þ/þ mice at day 7, 5.170.9 vs. 3.870.1, P¼0.2; at day 14,
5.570.1 vs. 1.970.1, Po0.005; day 30, 3.170.04 vs. 1.270.1,
Po0.005 (Fig. 1, right lower panel).
Splenic lymphocytes from DNAM-1 / and DNAM-1 þ/þ
mice effectively generated a robust MHC-restricted CD8 T cell
response in the absence of CD4 T cells. For these experiments,
500 mg of antibody to CD4 T cells was administered at day-2 and
day-0 with 200 mg given at days -1, þ3, and þ5. This regimen
ablated 499% of CD4 T cells. The results of CD4 T cell depletion
indicate that virus-speciﬁc CD8 T cells themselves in the absence
of CD4 T cells from either DNAM-1 / or DNAM-1 þ/þ mice,
7 day after a primary challenge with 1105 PFU of LCMV ARM
generated robust CTL responses, lyse LCMV infected target cells in
the presence or absence of CD4 T cells and purged virus in all mice
by 7 to 15 days post-infection.
DNAM-1  / and DNAM-1 þ /þ mice generate robust virus-speciﬁc
H-2b-restricted CTL memory response following primary infection
with LCMV ARM
Although only virus-speciﬁc CD8 CTL are required to control
an acute infection, both virus-speciﬁc CD8 and CD4 T cells are anabsolute requirement to purge virus and terminate a persistent
infection (Berger et al., 2000; Matloubian et al., 1994; Tishon
et al., 1995). We next compared the ability of DNAM-1 / and
DNAM-1 þ/þ mice to generate memory CTL 42 days after a
primary 1105 PFU i.p. challenge with LCMV ARM. At that time
DNAM-1 / LCMV-speciﬁc CD8 T cells had signiﬁcantly less
TNF-a and IL-2 than DNAM-1 þ/þ CD8 T cells. For these studies,
mice from both groups were given a booster challenge of
2106 PFU of LCMV Cl 13 i.p. at day 42 post-primary (P1)
inoculation followed by functional analysis of their memory CTL
in a 51Cr-release assay 3, 5, and 12 days post-S1 challenge. By
then, DNAM-1 / and DNAM-1 þ/þ mice generated robust
H-2b-restricted CTL immune memory responses at all three S1
time points measured. At day 3 S1 the percent 51Cr-release (four
mice/group, effector to target ration 50:1, mean71 SD) for
DNAM-1 / vs. DNAM-1 þ/þ was 4773 vs. 3377; at day
5 S1 7073 vs. 6272; at day 12 3574 vs. 3372. We then used
the day 5 S1 challenge for the remainder of our effector memory
studies. The use of activation markers CD127 and CD62L along
with tetramer analysis indicated that over 99% of virus-speciﬁc
GP 33 CD8 T cells and over 98% of virus-speciﬁc GP 67 CD4 T cells
were activated during S1 challenge. Fig. 3 display the results for
virus-speciﬁc memory CD8 and CD4 T cells that were activated
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Fig. 2. Defect in the expression of TNF-a and IL-2 in LCMV-speciﬁc GP 33 CD8 T cells in DNAM-1 / mice at days 7, 14, and 30 following primary challenge with
1105 PFU of LCMV ARM. Upper panel on the left shows representative FACS data from one of ﬁve DNAM-1 / mice for expression of TNF-a and IL-2 in the cytosol of
LCMV-speciﬁc GP 33 CD8 T cells from DNAM-1 / and DNAM-1 þ/þ mice at day 14 post-LCMV challenge. The lower left panel shows the combined data for DNAM-1
/ and DNAM-1 þ/þ groups (5 mice/group: meanþ1 SD). A signiﬁcant defect (Po0.005) in TNF-a and IL-2 occurs in LCMV-speciﬁc GP 33 CD8 T cells at days 7, 14, and
30 in DNAM-1 / mice when compared to DNAM-1 þ/þ mice. The right panels show that only at day 14 post-LCMV primary challenge is there a signiﬁcant difference
in heightened expression of TNF-a and IL-2 in GP 61 CD4 T cells in DNAM-1 / mice over that seen in GP 61 CD4 T cells from DNAM-1 þ/þ mice. Upper panel on the
right shows representative FACS data from one of ﬁve mice while the lower right panel displays the meanþ1 SD of each group of ﬁve mice. Experiments performed twice.
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equivalent between DNAM-1 / and DNAM-1 þ/þ secondary
GP 33 CD8 and GP 61 CD4 T cells. However, TNF-a and IL-2
expression were signiﬁcantly reduced in DNAM-1 / GP 33
CD8 T memory cells when compared to memory cells from
DNAM-1 þ/þ GP 33 CD8 T cells (Fig. 3). There was no difference
in expression of TNF-a or IL-2 between GP 61 CD4 T memory
cells from DNAM-1 / mice compared to DNAM-1 þ/þ mice
(Fig. 4). In addition to documenting outcomes for the immuno-
dominant GP 33 CD8 T cell subset we also analyzed the two other
CD8 immunodominant Db-restricted CD8 CTL: nucleoprotein (NP)
396 which recognizes LCMV NP aa 396–404, GP 276 which
recognizes LCMV GP aa 276–286 (Oldstone, 2002; Oldstone
et al., 1988; Yanagi et al., 1992), and the subdominant CTL
epitopes GP 92–101, GP 118–125, and NP 118–125 (van der
Most et al., 2003; van der Most et al., 1998).
Peptide stimulation and analysis of production of IFN-g in
memory LCMV-speciﬁc immunodominant or subdominant CD8
T cells revealed no signiﬁcant difference of IFN-g production
between DNAM-1 / and DNAM-1 þ/þ mice. IFN-g DNAM-1
/ vs. DNAM-1 þ/þ GP 33 11.370.6 vs. 10.270.9, P¼0.3
(Fig. 3); GP 276 9.870.5 vs. 9.270.9, P¼0.6; NP 396 25.8 vs.
25.3, P40.5; GP 118 1.870.2 vs. 1.970.2, P¼40.5; GP 92
1.570.1 vs. 1.570.05, P¼40.5; NP 118 1.370.2 vs. 1.270.2,
P40.5. However, analysis of GP 33 and GP 276 virus-speciﬁc CD8
T cells showed a signiﬁcant difference in the combined expression
of IFN-g/TNF-a and IL-2 in DNAM-1 / mice compared to
DNAM-1 þ/þ mice. That is, GP 33 DNAM-1 / mice had
670.6 of virus-speciﬁc CD8 T cells that expressed all threecytokines vs. 970.5 of DNAM-1 þ/þ mice, P¼0.02. For the other
immunodominant GP CD8 T cells, GP 276, DNAM-1 / 870.6
vs. DNAM-1 þ/þ 1170.9, P¼0.03. No defect was observed in
immunodominant virus-speciﬁc CD4 T cell populations GP 67
DNAM-1 / 5272 vs. DNAM-1 þ/þ 5572, P¼0.3.
Comparison of the anti-LCMV T cell response in DNAM-1  / and
DNAM-1 þ /þ mice following infection with the immunosuppressive
variant LCMV Cl 13
For the last series of experiments, we infected 8-week-old
DNAM-1 / (10 mice) and DNAM-1 þ/þ (5 mice) with
2106 PFU of LCMV Cl 13, an immunosuppressive variant of
LCMV ARM 53b, that causes a persistent infection (Ahmed and
Oldstone, 1988; Oldstone, 2002; Oldstone and Campbell, 2011).
Persistent infection usually lasts 60–100 or more days and then is
spontaneously cleared in over 90% of inoculated mice. In contrast,
inoculation of 2106 PFU of LCMV ARM leads to virus clearance
by 15 to 30 days. As expected, by 15 days post-infection with
2106 PFU i.v. of LCMV ARM, all ﬁve DNAM-1 / and ﬁve
DNAM-1 þ/þ mice cleared the infection and remained virus-free
for the next 30 days observation period. In contrast, all DNAM-1
/ mice and DNAM-1 þ/þ mice inoculated with LCMV Cl 13
still carried 104–105 PFU/ml of the virus in their sera at day 30
post-inoculation. By day 45, one of the DNAM-1 þ/þ mice had
cleared infection and by day 60 all DNAM-1 þ/þ mice purged the
virus. In contrast, by day 45 none of the DNAM-1 / mice
cleared the virus, although 7 of 10 were clear by day 60 and 9 of
10 by day 90. More importantly, DNAM-1 þ/þ mice documented
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Fig. 3. DNAM-1 / and DNAM-1 þ/þ mice generate robust secondary LCMV-speciﬁc CD8 T cell (GP33) and CD4 T cell (GP67) responses but GP 33 CD8 T cells from
DNAM-1 / mice show a defect in expression of TNF-a and IL-2. DNAM-1 / and DNAM-1 þ/þ mice received a primary LCMV challenge with 1105 PFU of LCMV
ARM i.p. Forty-two days later mice received a secondary challenge of 1106 PFU of LCMV Cl 13 i.v. and spleens were harvested ﬁve days later. Lymphocytes obtained from
the spleen were stimulated with either peptide GP 33–41 or GP 61–80 as reported (Brooks et al., 2006; Homann et al., 2001). Panel on left shows the signiﬁcant decrease in
TNF-a and IL-2 in DNAM-1 / mice compared to DNAM-1 þ/þ mice at ﬁve days post-secondary response (left lower groups of ﬁve mice with meanþ1 SD). The left
upper panel shows FACS data for expression of interferon-g from one representative GP 33 CD8 CTL obtained from DNAM-1 / and DNAM-1 þ/þ mice. There was no
defect in expression of interferon-g in these mice. The panel on the right shows interferon-g, TNF-a, and IL-2 data for GP 61 CD4 T cells obtained ﬁve days after secondary
LCMV challenge and shows there is no signiﬁcant differences in GP 61 CD4 T cells harvested from DNAM-1 / compared to DNAM-1 þ/þ mice.
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/ mice at days 30, 45, and 60 post-Cl 13 challenge (po0.001
at each time point) (Fig. 4). Thus, DNAM-1 / mice require a
signiﬁcantly longer interval to spontaneously purge the Cl 13
infection, which eventually disappeared. These results point to a
subtle but deﬁnitive and signiﬁcant defect in virus-speciﬁc CD8 T
cells from DNAM-1 / mice that was responsible for their delay
in clearance of infection, i.e., its persistence.
For the ﬁnal experiment we adoptively transferred immune
memory CD8 and CD4 T cells from DNAM-1 / and DNAM-1
þ/þ mice into DNAM-1 þ/þ persistently infected mice. Results
shown in Fig. 4A indicated that at 15 day post-transfer neither of
the six DNAM-1 þ/þ mice receiving 2107 DNAM-1 þ/þ
immune memory cells nor the six DNAM-1 þ/þ mice receiving
2107 DNAM-1 / immune memory cells cleared virus,
although DNAM-1 þ/þ memory cells were more efﬁcient in that
they lowered virus titers by more than one log compared to
DNAM-1 / memory cells. By 30 days post-adoptive transfer all
six mice receiving DNAM-1 þ/þ memory cells cleared virus
while in contrast, only one of six mice receiving DNAM-1 /
memory cells cleared virus. By day 93, ﬁve of six DNAM-1 /
persistently infected mice cleared virus.Discussion
Here we report that mice devoid of DNAM-1 gene expression
have a signiﬁcant and reproducible decrease in the expression of
TNF-a and IL-2 in their CD8 T cells following an acute infection
with LCMV ARM (Figs. 1 and 2). These defects did not translate
into a failure to terminate the acute viral infection. We note, for
the ﬁrst time, that in the absence of the DNAM-1 gene LCMV-speciﬁc CD4 T cells displayed signiﬁcantly enhanced amounts of
IFN-g, TNF-a, and IL-2 in their cytoplasms. However, biologic
signiﬁcance of the upgraded cytokine expression is not clear.
Virus-speciﬁc CD8 cells showing deﬁciencies in TNF-a and IL-2
did not rely on CD4 T cells for assistance in controlling the acute
viral infection as shown by the CD4 T cell depletion studies.
However, importantly and of biologic signiﬁcance the defects of
TNF-a and IL-2 in virus-speciﬁc CD8 T cells are associated with a
signiﬁcant delay in spontaneous purging virus from DNAM-1 /
mice when compared to DNAM-1 þ/þ mice following a persistent
LCMV Cl 13 infection. More to the point, adoptive transfer of
immune memory cells from DNAM-1 / mice carrying the defect
in TNF-a and IL-2, display a deﬁciency in terminating the persistent
viral infection of DNAM-1 þ/þ mice.
Earlier, Cella et al. (2010) reported that persistent LCMV Cl 13
infection resulted in a loss of DNAM-1 expression on PD-1high CD8
T cells speciﬁc for the H-2Db-restricted GP 33 immunodominant
LCMV ARM or Cl 13 CTL epitope. We extended their ﬁndings by
examining the impact of lost DNAM-1 expression on either the
spontaneous clearance of Cl 13 persistent infection or clearance of
Cl 13 persistent infection after adoptive transfer of immune
memory lymphocytes. Comparing the spontaneous clearance of
Cl 13 persistent infection in DNAM-1 sufﬁcient and DNAM-1
knock-out mice indicated that although both groups of mice
cleared virus, they did so with different kinetics. DNAM-1
deﬁcient mice showed a signiﬁcant lag period for the time
required to purge virus and terminate the persistent infection.
Expanding upon this observation we noted that adoptively
transferred immune memory cells from DNAM-1 deﬁcient mice
were markedly less efﬁcient in purging LCMV Cl 13 virus and
terminating the persistent infection in DNAM-1 þ/þ mice than
equivalent numbers of immune memory cells from DNAM-1
Fig. 4. DNAM-1 / mice persistently infected with LCMV Cl 13 have a defect in purging virus. Panel A shows the results of adoptive transfer of 2107 immune memory
splenocytes obtained from either DNAM-1 / or DNAM-1 þ/þ mice transferred into DNAM-1 þ/þ mice. At time of transfer the host DNAM-1 þ/þ mice carried
3105 PFU of LCMV in their sera. By 15 days post-transfer of DNAM-1 þ/þ immune memory cells (blue) virus had not cleared from any of the six host mice but viral titer
was reduced nearly 2 logs (3105 to 6103). By day 30 virus was cleared from all mice. In contrast, adoptive transfer of immune memory cells from DNAM-1 / mice
was reduced less than 1 log (3105 to 9104) at day 15 and virus was still present in 50% of mice by day 62. Similar results with repeated experiment. Panel B shows that
failure to clear was not due to allogeneic difference between DNAM-1 / and DNAM-1 þ/þ mice. Panel C displays that spontaneous clearance of persistent LCMV Cl 13
infection in DNAM-1 / mice was signiﬁcantly delayed when compared to spontaneous clearance in DNAM-1 þ/þ mice. For this experiment 10 DNAM-1 / and ﬁve
DNAM-1 þ/þ mice were inoculated with LCMV Cl 13 2106 PFU i.v. and displayed equivalent amounts of virus in their sera at day 7. DNAM-1 þ/þ mice infected with
LCMV Cl 13 spontaneously lowered viral titers and cleared infection signiﬁcantly better (signiﬁcance Po0.005, marked by asterisks) than DNAM-1 / mice. Mice serially
bled and the amount of virus carried by each group over time is quantiﬁed by plaque assay. See (Ahmed and Oldstone, 1988) for details. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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requires both immune CD8 and CD4 T cells (Berger et al., 2000;
Matloubian et al., 1994; Tishon et al., 1995) with no or limited
evidence that B cells or antibody are required (Homann et al.,
1998). For clearance, a minimal number of 350,000 functional
immune CD8 T cells and 7000 functional CD4 T cells are needed
(Berger et al., 2000). To evaluate the functional capacity of virus-
immune CD8 and CD4 T cells, we studied their cytolytic capacity
in a 51Cr-release assay and their expression of IFN-g, TNF-a, and
IL-2 in the cytoplasm of CD8 and CD4 immune T cells (Brooks
et al., 2006; Homann et al., 2001). We found that immune
memory CD8 and CD4 T cells from DNAM-1 þ/þ or DNAM-1
/ mice were equal in cytolytic activity against virus-infected
cells. In contrast, CD8 immune T cells reactive to GP 33 and GP
276 epitopes from DNAM-1 / mice showed a signiﬁcant
decrease in their cytoplasmic expression of TNF-a and IL-2 when
compared to the expression of these molecules in corresponding
immune CD8 T cells from DNAM-1 þ/þ mice. No signiﬁcant
differences in cytoplasmic expression of IFN-g, TNF-a, or IL-2 was
noted in memory CD4 GP 67 T cells when DNAM-1 þ/þ mice
were compared to DNAM-1 / mice.
Clearance of persistent LCMV Cl 13 infection requires both
IFN-g and TNF-a (Berger et al., 2000; Lauterbach et al., 2006;
Tishon et al., 1995). Further, we transferred 5-fold more immune
memory CD8 and CD4 DNAM-1 / T cells to DNAM-1 persis-
tently infected mice over the minimal numbers required to clear
the persistent LCMV infection (Berger et al., 2000). Yet, immune Tcells from DNAM-1 / mice still were unable to terminate
the persistent infection while transferred DNAM-1 þ/þ immune
cells did indicating that the intrinsic T cell defect of TNF-a and
IL-2 in DNAM-1 / CD8 T cells was the likely culprit. Micro-
satellite mapping conﬁrmed C57Bl/6 (H-2b) background for
DNAM-1 / mice and match DNAM-1 þ/þ mice, coupled with
experimental evidence showing no allogeneic MLR reaction
(Materials and Methods) (Fig. 4), argue that the TNF-a defect
which is known to be important in clearance of persistent LCMV
infection (Lauterbach et al., 2006) or perhaps additional defects in
other cytokines or chemokines (Brooks et al., 2006; Tishon et al.,
1995) played important roles in the failure to clear the persistent
infection. Further, the differences observed where DNAM-1 /
CD8 T cells are more successful in spontaneously clearing the
persistent infection than by adoptive immunotherapy suggest that
the requirement to successfully terminate infection by these two
different approaches either require additional factors for viral
clearance or that more IFN-g and TNF-a are required for the
adoptive transfer as compared to amounts needed for spontaneous
clearance. Lastly, DNAM-1 is an adhesion molecule on NK cells
(Magri et al., 2011; Pende et al., 2006) and NK cells have recently
been shown to regulate virus-speciﬁc CD8 T cells in LCMV infection
(Lang et al., 2012; Waggoner et al., 2011). Whether DNAM-1 /
NK cells play a role in the events described here is not known. The
signiﬁcance of DNAM-1 molecule in NK/CD4/CD8 T cell interaction
and activity in persistent LCMV and other viral infection awaits
future exploration.
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signiﬁcant defects in but not total deletion of inﬂammatory
cytokine TNF-a and of IL-2 in virus-speciﬁc CD8 T cells. The
effectiveness of multifunctional TH1 cells as correlates of protec-
tion (Darrah et al., 2007) and the sequential loss in polyfunction-
ality or hierarchical T cell exhaustion proﬁle of ﬁrst IL-2, and TNF-
a in the absence of IFN-g loss observed in virus-speciﬁc CD8 T
cells obtained with LCMV infected DNAM-1 / mice mirrors
reports for other chronic infections (Seder et al., 2008; Wherry,
2011). The CD8 T cell defect in DNAM-1 / mice results in a
biologic activity where additional time was required to purge
virus from infected cells in vivo and terminate the infection. Our
ﬁndings also provide leads for amounts of IFN-g, TNF-a, and IL-2
cytokines that activated CD8 T cells need to overcome viral
infection and found, moreover, that even lesser amounts pro-
duced in DNAM-1 / mice effectively controlled an acute or
spontaneously cleared a persistent viral infection but were not
successful to complete clearance following adoptive immune
memory cell transfer.Materials and methods
Mice
C57BL/6J (DNAM-1 þ/þ) mice were obtained from the rodent
breeding colony at The Scripps Research Institute. DNAM/ ,
described previously (Gilﬁllan et al., 2008), were veriﬁed by PCR
reactions on DNA puriﬁed from tail biopsies. The DNAM-1 deletion
made in 129 mice was backcrossed onto a C57Bl/6 background,
facilitated by a genome-wide screening of polymorphic microsatel-
lite markers at 10-centiMorgan intervals at each generation (per-
formed by the Rheumatic Disease Core Center’s Speed Congenics
Laboratory, Washington University School of Medicine). A 96%
C57Bl/6 male (B6N4) was identiﬁed for further backcrossing;
B6N6 heterozygotes were intercrossed to generate the DNAM-1
/ mice. Immunologic MHC compatibility between DNAM-1
/ and DNAM-1 þ/þ male mice was judged by the criteria that
there was no evidence of a positive mix leukocyte reaction between
DNAM-1 / and DNAM-1 þ/þ mice. The total spleenic T cells,
CD8 and CD4, were equivalent in DNAM-1 / and DNAM-1 þ/þ
resting mice or after primary or secondary virus challenge. Mice
were maintained in pathogen-free conditions and handled according
to the requirements of the National Institutes of Health and The
Scripps Research Institute animal care and use committee.
51Cr release
Splenocytes were obtained from mice infected with LCMV
Armstong and/or LCMV Clone 13. Target cells, matched MC57
(H-2b) and unmatched Balb Cl 7 (H-2d), were infected with LCMV
for 48 h at MOI 1. Effector/target ratios were 50:1, 25:1, 12.5:1, 6.3:1
and assay was done in triplicate. Cells were incubated for 5 h at
37 1C. One hundred microliter supernatant was measured for
speciﬁc 51Cr counts. See (Ahmed and Oldstone, 1988) for details.
Adoptive transfer
To establish a persistent infection, recipient mice were
injected i.v. with 2106 LCMV Clone 13. Twenty days after LCMV
Cl 13 injection, mice were bled and virus in sera plaqued to insure
that recipients were persistently infected prior to receiving
2107 immune memory cells i.p. from donor mice. Donor mice
were injected with 105 PFU LCMV Armstong i.p. At 42 days post
inoculation the mice were boosted with 105 PFU LCMV Arm-
strong. Five days post viral boost, spleens were harvested tocreate single cell suspensions. See (Berger et al., 2000; Tishon
et al., 1995) for details.
Peptide simulation
Spleens were disrupted though 100 mm ﬁlters, cleared of RBC
and incubated for 5 h at 37 1C with 100 U/ml IL-2, 4 mg/ml
Brefeldin-A, and 2 mg/ml of MHC class I peptide LCMV-GP33–41,
LCMV-NP396–404, LCMV-GP276–286, LCMV-GP92–101, LCMV-GP118–125,
or 5 mg/ml MHC class II peptide LCMV-GP61–80. See (Brooks et al.,
2006; Homann et al., 2001) for details.
Antibodies and tetramers
The following antibodies were purchased from either eBios-
ciences (San Diego, CA) or BD Biosciences (San Jose, CA): Paciﬁc
Blue-CD4, Paciﬁc Blue-CD8, FITC-90.2, PE-TNFa, PEcy7–62L,
PEcy7-IFNg, APC-IL-2, CD16/32 Fc block. Cells were surface
stained in 1% FBS in PBS and ﬁxed/permeabilized with BD
cytoﬁx/cytoperm kit for intracellular staining. Biotinylated tetra-
mers, obtained from the NIH core facility, were tetramerized with
streptavidin-APC. Cells were incubated with MHC class I tetra-
mers GP33–41, NP396–404, GP276–286 for 1 h on ice or MHC class II
tetramer GP61–80 for 1 h at room temperature. Flow cytometry
was done on a LSR-II ﬂow cytometer (BD Biosciences) and
analyzed with Flowjo software (Tree Star, Inc.). See (Brooks
et al., 2006; Homann et al., 2001) for details.
Viruses, infection and titration
LCMV Armstrong, and LCMV Clone 13 were grown at MOI
0.1 on BHK cells for 48 h. Virus was puriﬁed of cellular debris by
low-speed centrifugation and stored in small aliquots at 80 1C.
Mice were infected with LCMV Arm i.p. 103, 105, i.v. 2106, or
LCMV Clone 13 i.v. 2106 PFU/ml. Serum was obtained by retro-
orbital bleeding followed by brief low speed centrifugation. Viral
titers in the serum were determined by plaque assay on Vero
monolayers in 6-well plates for 1 h as described previously
(Salvato et al., 1991).
CD4 depletion
Anti-CD4 Ab was obtained from the Ab core Facility at The
Scripps Research Institute. Mice were i.p. injected with 500 mg on
days -2, 0 and 200 mg on days -1, 3, and 5. Degree of deletion was
499% as determined by FACS on serum samples.Acknowledgments
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